Immunotherapy before surgery shows promise against rare skin cancer

NCT ID NCT05496036

Recruiting now Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Feb 22, 2026 · Last updated May 21, 2026 · Updated 12 times

Summary

This study is for people with Merkel cell carcinoma, a rare skin cancer, that can be removed with surgery. The goal is to see if giving the immunotherapy drug pembrolizumab before and after surgery can shrink the tumor and lower the chance of the cancer coming back. About 15 participants will receive one dose of pembrolizumab before surgery, then continue after surgery, and researchers will monitor side effects and how well the tumor responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MERKEL CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Penn Medicine
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MERKEL CELL CARCINOMA